Celltrion Healthcare: Biosimilars Have the Potential to Deliver Dramatic Cost Savings for US and European Healthcare Systems

As the global leader in biosimilars, Celltrion Healthcare aims to
positively shape future healthcare by improving patient access to

LONDON–(BUSINESS WIRE)–Celltrion Healthcare outlined their vision of ‘shaping future healthcare
by improving access to biosimilars’ at the 5th Annual
Biosimilars USA Conference in New Jersey, US.

Biosimilars offer healthcare providers and patients greater treatment
choice and value, better access to treatments and improved patient
outcomes. According to data provided by IMS Health, biosimilars could
lead to cumulative savings of up to 107 billion USD by 2020 in the
United States (US) and the top five European Union (EU) countries.1
The EU has made significant progress in unlocking the potential of
biosimilars through continuous education of providers, payers and
patients. This has been critical to EU biosimilar acceptance but has not
been seen in the US, which has lagged behind.

During a presentation on the opportunities and challenges presented by
the use of biosimilars in the US, Celltrion Healthcare highlighted
several challenges affecting the uptake of biosimilars within the US
market. Both physicians and patients in the US lack confidence in
biosimilars due to a low level of education and awareness. According to
a survey, 67% of patients said they were “unaware” of biosimilars and
70% selected “no” as a response to the statement “is a biosimilar is
safe?”2,3 Compounding this lack of understanding are
anti-biosimilar campaigns running in the US which are increasing the
negative public perception of biosimilars. In addition, legal battles
like patent litigation have restricted uptake of biosimilars and have
hindered progress in the US.

The lower cost of biosimilars means that more patients can receive
effective treatments without increasing healthcare budgets. Furthermore,
treatment at a lower cost generates savings that can be put towards
funding innovative treatments or combination treatments, ultimately
benefitting more patients and on a longer-term basis.

“A key factor in overcoming barriers to US market entry is sharing the
positive experiences of both healthcare professionals and patients. In
particular, it is important to highlight best practice and work together
to ensure as many patients as possible in the US have access to
treatment through the use of high quality, more cost-effective
biosimilars,” said Mr HoUng Kim, Head of Strategy and Operations
Division, Celltrion Healthcare. “As innovators within the biosimilar
field, we are looking forward to launching subcutaneous infliximab next
year. We expect that this will generate further cost savings in addition
to improved convenience as dual formulations would provide personalised
therapeutic approaches to optimise patient outcomes.”

At the International Society for Pharmacoeconomics and Outcomes Research
(ISPOR) 2018 which took place last week in Barcelona, Spain, Celltrion
Healthcare presented new financial forecast data, which showed European
health services could save hundreds of millions of euros through the use
of biosimilars. For example, predicted budgetary savings in the 28
countries of the European Union with trastuzumab biosimilar, range from
€872 million to €2,635 million, which would allow up to an additional
134,000 patients to gain access to trastuzumab over a five-year period.4

Speaking at ISPOR, Professor Gulácsi, Head of Department of Health
Economics, Corvinus University of Budapest, Hungary, discussed the long
term benefits and cost-effectiveness of TNFi treatment, including
biosimilar infliximab, in methotrexate-naïve patients with rheumatoid
arthritis (RA), “Our systematic review and meta-analysis has
demonstrated the long-term benefits of TNFi treatment versus other
treatment strategies in methotrexate-naïve patients with RA. Results
from our probabilistic Markov model demonstrated that biosimilar
infliximab in early RA is cost effective in Denmark, Finland, Sweden,
Norway, France, Germany, Italy, Spain, the United Kingdom and
Hungary. Infliximab biosimilar intravenous is the most cost effective
option at this time, and I believe that this advantage will be further
strengthened by the introduction of subcutaneous formulation.”

“Budget impact modelling is an important tool when assessing the
financial impact of biosimilars,” said Aidan Byrne, Consultant, Health
Economics and Outcome Research / Real-World Insights, IQVIA, United
Kingdom. “Due to the significant cost-saving we have seen to date, the
role that biosimilars play in improving the sustainability of healthcare
systems is clear.”

— Ends—

Notes to editors:

About rheumatoid arthritis
In Europe, more than 2.9 million
people have rheumatoid arthritis (RA), many of whom are of working age.
On average, every third person with RA becomes work disabled and up to
40 per cent leave work completely within 5 years of diagnosis.5
Although there is no cure for RA, there are many treatments that can
reduce inflammation and ease pain. As with all rheumatic diseases early
diagnosis and intervention is key.

About CT-P13 (biosimilar infliximab)
CT-P13 is developed and
manufactured by Celltrion, Inc. and was the world’s first monoclonal
antibody biosimilar approved by the European Commission (EC). It is
indicated for the treatment of eight autoimmune diseases including
rheumatoid arthritis and IBD. It was approved by the EC under the trade
name Remsima® in September 2013 and launched in major EU
countries in early 2015. The US FDA approved CT-P13 in April 2016 under
the trade name Inflectra®. CT-P13 is approved in more than 88
countries (as of August 2018) including the US, Canada, Japan and
throughout Europe.

About Celltrion Healthcare
Celltrion Healthcare is committed
to delivering innovative and affordable medications to promote patients’
access to advanced therapies. Its products are manufactured at
state-of-the-art mammalian cell culture facilities, designed and built
to comply with the US FDA cGMP and the EU GMP guidelines. Celltrion
Healthcare endeavors to offer high-quality cost-effective solutions
through an extensive global network that spans more than 120 different
countries. For more information please visit: http://www.celltrionhealthcare.com/


1 Delivering on the potential of biosimilar medicines—The
role of functioning competitive markets IMS institute for healthcare
informatics; 2016
2 Cohen H, Beydoun D, Chien D, et al.
Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty
Physicians. Adv Ther. 2016;33(12):2160-2172.
3 Jacobs I,
Singh E, Sewell KL, Al-sabbagh A, Shane LG. Patient attitudes and
understanding about biosimilars: an international crosssectional survey.
Patient Prefer Adherence. 2016;10:937-48
4 Suh D, Suh
DC, Lee SM. PCN69:
Budget Impact of Substituting Biosimilar Trastuzumab (CT-P6) In Treating
Gastric Cancer and Breast Cancer in 28 European Countries. Poster
presented at: ISPOR Europe 2018.
5 NRAS, European Fit
for Work Report. Available at www.nras.org.uk/european-fit-for-work-report.
[Accessed Aug, 2018].


Emma Gorton
[email protected]
203 817 6791

Georgia Featherston
[email protected]
203 817 6718


Content is the most important part of having quality links to your website. With Area-Info.net, we provide a quality location to share your story and include links to your website to help you grow. If you would like to learn more, visit this page to see how you can use Area-Info.net to rank higher and quicker in search engines. Contact me directly at [email protected] with any questions, or to schedule speaking engagements.